What should be given to a patient with a high antistreptolysin O (ASO) titer of 225 IU/mL and urticaria?

Treatment Approach for High ASO (225 IU/mL) with Urticaria

Treat the urticaria with standard second-generation H1-antihistamines as first-line therapy, escalating to omalizumab if needed, while recognizing that the elevated ASO titer likely represents a past streptococcal infection that does not require antibiotic treatment in the absence of active pharyngitis. 1

Understanding the Clinical Context

The ASO titer of 225 IU/mL indicates prior streptococcal exposure but does not guide urticaria management. Here's why this matters:

ASO Titer Interpretation

• ASO titers reflect past immunologic events, not current infection 2
• ASO begins rising ~1 week after infection and peaks at 3-6 weeks, persisting for months even after uncomplicated infections 2
• Your patient's value of 225 IU/mL falls within normal ranges for many populations (ULN ranges from 210-515 IU/mL depending on age and geography) 3, 4
• Critical point: Elevated ASO cannot determine if someone is truly infected versus merely a streptococcal carrier 2

The Urticaria Connection

While one case report describes urticaria with elevated ASO in adult-onset Still's disease 5, this is an exceedingly rare presentation requiring fever, joint pain, and other systemic features. In that case, the ASO remained elevated despite clinical remission, suggesting it was coincidental rather than causative 5.

Treatment Algorithm for the Urticaria

Step 1: First-Line Treatment

Start with standard-dose second-generation H1-antihistamines 1

• If symptoms are intolerable, escalate immediately
• Otherwise, assess control after 2-4 weeks using the Urticaria Control Test (UCT)

Step 2: Inadequate Control (UCT <16)

Increase antihistamine dose up to 4-fold the standard dose 1

• This is the recommended second step before moving to biologics
• Continue for adequate trial period

Step 3: Persistent Inadequate Control

Initiate omalizumab 300 mg subcutaneously every 4 weeks 1

• This is now second-line therapy per 2022 guidelines
• Allow up to 6 months for response
• If insufficient response, consider updosing:
  • Shorten interval and/or increase dose
  • Maximum: 600 mg every 14 days
  • Higher doses particularly beneficial in patients with high BMI

Step 4: Omalizumab Failure

Consider cyclosporine only after failure of higher-than-standard omalizumab doses 1

• Monitor blood pressure and renal function (BUN, creatinine) every 6 weeks
• Be aware of risks: hypertension, seizures in predisposed patients, hirsutism, gum hypertrophy, renal failure

When NOT to Treat the Streptococcal Infection

Do not give antibiotics based solely on elevated ASO with urticaria unless:

• Active pharyngitis is present with positive rapid antigen test or throat culture
• Clinical suspicion for acute rheumatic fever (requires Jones criteria)
• Signs of post-streptococcal glomerulonephritis

The ASO titer alone does not indicate need for antibiotic therapy 2.

Common Pitfalls to Avoid

• Don't misinterpret ASO as indicating active infection requiring antibiotics - it reflects past exposure only
• Don't skip antihistamine updosing - jumping straight to omalizumab bypasses effective, lower-cost therapy
• Don't use cyclosporine before adequate omalizumab trial - the risk-benefit profile favors omalizumab 1
• Don't forget that normal ASO ranges are higher in children and vary by geography 3, 4

Step-Down Strategy

Once complete control is achieved (UCT ≥16 for ≥3 consecutive months):

• Reduce antihistamine dose by no more than 1 tablet per month
• If breakthrough symptoms occur, return to last effective dose
• Use "as much as needed, as little as possible" approach 1